Trellus Health has released unaudited interim results for the six months ended 30 June 2025. Financial performance shows revenue of $295k, a significant improvement over H1-24 ($50k) and an adjusted EBITDA loss of $3.5m. Cost control has been a key focus, with a further c.10% reduction in cash burn since August extending the runway into early November 2025. While the accounts flag a material uncertainty should funding not be secured, the Board has confirmed its intention to explore a fundraising. Cash at period-end was $1.6m (Dec 2024: $4.3m). Positive commercial momentum is encouraging, underpinned by recent wins including Johnson & Johnson, Pfizer and a leading global CRO.
